University of Oklahoma Health Sciences Center, Oklahoma City, OK 73190, USA.
J Clin Oncol. 2012 Mar 1;30(7):695-700. doi: 10.1200/JCO.2011.38.8645. Epub 2012 Jan 30.
The primary objective was to establish noninferiority of laparoscopy compared with laparotomy for recurrence after surgical staging of uterine cancer.
Patients with clinical stages I to IIA disease were randomly allocated (two to one) to laparoscopy (n = 1,696) versus laparotomy (n = 920) for hysterectomy, salpingo-oophorectomy, pelvic cytology, and pelvic and para-aortic lymphadenectomy. The primary study end point was noninferiority of recurrence-free interval defined as no more than a 40% increase in the risk of recurrence with laparoscopy compared with laparotomy.
With a median follow-up time of 59 months for 2,181 patients still alive, there were 309 recurrences (210 laparoscopy; 99 laparotomy) and 350 deaths (229 laparoscopy; 121 laparotomy). The estimated hazard ratio for laparoscopy relative to laparotomy was 1.14 (90% lower bound, 0.92; 95% upper bound, 1.46), falling short of the protocol-specified definition of noninferiority. However, the actual recurrence rates were substantially lower than anticipated, resulting in an estimated 3-year recurrence rate of 11.4% with laparoscopy and 10.2% with laparotomy, or a difference of 1.14% (90% lower bound, -1.28; 95% upper bound, 4.0). The estimated 5-year overall survival was almost identical in both arms at 89.8%.
This study previously reported that laparoscopic surgical management of uterine cancer is superior for short-term safety and length-of-stay end points. The potential for increased risk of cancer recurrence with laparoscopy versus laparotomy was quantified and found to be small, providing accurate information for decision making for women with uterine cancer.
主要目的是确立腹腔镜相对于开腹手术在子宫癌手术分期后复发方面的非劣效性。
临床分期为 I 期至 IIA 期的患者被随机分配(2:1)接受腹腔镜(n=1696)或开腹手术(n=920)进行子宫切除术、输卵管卵巢切除术、盆腔细胞学检查以及盆腔和腹主动脉旁淋巴结切除术。主要研究终点是无复发生存期的非劣效性,定义为与开腹手术相比,腹腔镜手术的复发风险增加不超过 40%。
在中位随访时间为 59 个月时,仍有 2181 名存活患者,其中 309 例(210 例腹腔镜;99 例开腹)复发,350 例(229 例腹腔镜;121 例开腹)死亡。腹腔镜相对于开腹手术的估计风险比为 1.14(90%下限,0.92;95%上限,1.46),未达到方案规定的非劣效性定义。然而,实际复发率远低于预期,导致腹腔镜组的 3 年复发率为 11.4%,开腹组为 10.2%,差异为 1.14%(90%下限,-1.28;95%上限,4.0)。在这两个治疗组中,5 年总生存率几乎相同,均为 89.8%。
本研究之前报告称,腹腔镜手术治疗子宫癌在短期安全性和住院时间终点方面具有优势。腹腔镜与开腹手术相比癌症复发风险的增加被量化,并发现风险很小,为子宫癌患者的决策提供了准确信息。